With our unique expertise in the ATRAG biology and holistic approach in diseases where the AT2 receptor has a central role in stopping and reversing disease pathology we fuel our pipeline with several assets with long patent life for a variety of diseases. Some of these could be partnered while others can be taken to the market by Vicore.